IL-5 synergies with IL-2 to produce increased LAK activity, although IL-5 alone induced little cytotoxic activity. The most dramatic synergy occurred with a suboptimal IL-2 concentration. The kinetics of LAK activity induced by IL-2 plus IL-5 were similar to those induced by IL-2. IL-5 exerted its effects during the late stage of IL-2 induced LAK generation. In the precursor phase, depletion of asialo-GM1+ cells preceding culture eliminated IL-2 plus IL-5 induced LAK activity. In the effector phase, IL-2 plus IL-5 induced LAK activity was eliminated by depletion of Thy1.2+ cells following culture.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3892/ijo.1.2.165 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors Associated with Persisting Post-Concussion Symptoms Among Collegiate Athletes and Military Cadets: Findings from the NCAA-DoD CARE Consortium.
Sports Med
January 2025
IU School of Optometry and Program in Neuroscience, Indiana University, Bloomington, IN, USA.
Background: Persisting post-concussion symptoms (PPCS) is a condition characterized by prolonged recovery from a mild traumatic brain injury (mTBI) and compromised quality of life. Previous literature, on the basis of small sample sizes, concludes that there are several risk factors for the development of PPCS.
Objective: We seek to identify protective and risk factors for developing slow recovery or persisting post-concussion symptoms (PPCS) by analyzing medical history, contact sport level, setting, and the Sport Concussion Assessment Tool (SCAT) and Brief Symptom Inventory (BSI-18) assessments at baseline and post-injury.
Real-world effectiveness of intravenous belimumab in adults with systemic lupus erythematosus: results of the observational OBSErve study in the Russian Federation.
BMC Rheumatol
January 2025
GSK Saudi Arabia, Value Evidence and Outcomes, Jeddah, Saudi Arabia.
Background: The real-world effectiveness of intravenous (IV) belimumab in treating systemic lupus erythematosus (SLE) has been demonstrated in various countries through the OBSErve (evaluation Of use of Belimumab in clinical practice SEttings) program. Here we describe the clinical effectiveness of IV belimumab for treating SLE in real-world clinical practice in the Russian Federation.
Methods: In the retrospective, observational OBSErve Russia study (GSK Study 215349), eligible physicians enrolled adults with SLE receiving IV belimumab as part of their standard care.
Recombinant expression and characterization of the family 5 cellulase from in BL21-CodonPlus (DE3)-RIPL.
Biochem Biophys Rep
March 2025
Institute of Biotechnology, Bioengineering and Food Systems, Advanced Engineering School, Far Eastern Federal University, Vladivostok, 690922, Russia.
B. velezensis RB. IBE29 is a chitinolytic bacterium originally isolated from agricultural soil of Vietnam.
View Article and Find Full Text PDFThe functional role of LncRNA HOXA-AS2 in multiple human cancers.
Pathol Res Pract
December 2024
Research Fellow School of Life Sciences, University of Sussex, Brighton, UK. Electronic address:
Humans have more than 270,000 lncRNAs. Among these, lncRNA HOXA-AS2 is considered a transformative gene involved in various cellular processes, including cell proliferation, apoptosis, migration, and invasion. Thus, it can be regarded as a potential tumor marker for both diagnosis and prognosis.
View Article and Find Full Text PDFA3AR antagonism mitigates metabolic dysfunction-associated steatotic liver disease by exploiting monocyte-derived Kupffer cell necroptosis and inflammation resolution.
Metabolism
December 2024
College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Chungbuk, South Korea. Electronic address:
Article Synopsis
- This study focused on how the adenosine A3 receptor (A3AR) influences the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) through the regulation of immune cells, particularly pro-inflammatory Kupffer cells derived from monocytes (MoKCs).
- Researchers found that inhibiting A3AR, either through a drug called FM101 or by genetic deletion, significantly improved liver inflammation and fibrosis in model mice.
- The results suggest that targeting A3AR may offer a novel therapeutic approach for treating MASLD by inducing cell death (necroptosis) in harmful immune cells, thereby promoting a healthier liver environment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!